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Background: Mesenchymal stromal cells attract much interest in tissue regeneration
because of their capacity to differentiate into mesodermal origin cells, their paracrine
properties and their possible use in autologous transplantations. The aim of this
study was to investigate the safety and reparative potential of implanted human
mesenchymal stromal cells (hMSCs), prepared under Good Manufacturing Practice
(GMP) conditions utilizing human mixed platelet lysate as a culture supplement, in a
collagenase Achilles tendon injury model in rats.
Methods: Eighty-one rats with collagenase-induced injury were divided into two
groups. The first group received human mesenchymal stromal cells injected into the
site of injury 3 days after lesion induction, while the second group received saline.
Biomechanical testing, morphometry and semiquantitative immunohistochemistry of
collagens I, II and III, versican and aggrecan, neovascularization, and hMSC survival
were performed 2, 4, and 6 weeks after injury.
Results: Human mesenchymal stromal cell-treated rats had a significantly better
extracellular matrix structure and a larger amount of collagen I and collagen III.
Neovascularization was also increased in hMSC-treated rats 2 and 4 weeks after
tendon injury. MTCO2 (Cytochrome c oxidase subunit II) positivity confirmed the
presence of hMSCs 2, 4 and 6 weeks after transplantation. Collagen II deposits and
alizarin red staining for bone were found in 6 hMSC- and 2 saline-treated tendons
6 weeks after injury. The intensity of anti-versican and anti-aggrecan staining did not
differ between the groups.
Conclusions: hMSCs can support tendon healing through better vascularization as
well as through larger deposits and better organization of the extracellular matrix.
The treatment procedure was found to be safe; however, cartilage and bone
formation at the implantation site should be taken into account when planning
subsequent in vivo and clinical trials on tendinopathy as an expected adverse event.
Keywords: Achilles tendon, Mesenchymal stromal cells, OsteogenesisBackground
Tendon pathologies are a common problem especially in people of working age. The
tendon healing process includes the formation of a hematoma, the local infiltration of
inflammatory cells, the release of cytokines and growth factors followed by the© 2014 Machova Urdzikova et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication
waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise
stated.
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organization of the tendon tissue. Various cell-based therapies have been used to treat
tendon pathologies in several in vivo studies [1-3] and at least one clinical trial
(OrthADAPT; ClinicalTrials.gov identifier NCT01687777). Clinically relevant cell-
based therapies often utilize adult stem cells, e.g. multipotent mesenchymal stromal
cells. Mesenchymal stromal cells of various origins have been implanted directly into a
tendon injury or attached to biodegradable scaffolds used to repair the tendon; they
have shown an apparent beneficial effect on the healing process [4] and migrated to
the injured tendon [5]. It was repeatedly shown that the delivery of mesenchymal stro-
mal cells can create an optimal environment to support tendon tissue regeneration via
the formation of extracellular matrix, enhanced vascularization, the production of sup-
porting factors, modulation of the immunoresponse and the replacement of damaged
cells [4,6].
Our aim was to describe the effect of the xenogeneic transplantation of human multipo-
tent mesenchymal stromal cells (hMSCs) prepared under Good Manufacturing Practice
(GMP) conditions on the healing process of rat Achilles tendons and also to identify
potential side effects of human mesenchymal cells (tumorigenesis, wrong differentiation
pathways) transplanted into a tendon injury to confirm the safety of hMSC treatment.Methods
Cell isolation and cultivation
hMSCs were isolated from the bone marrow of healthy human donors. All procedures
for hMSC preparation were performed under GMP in the spin-off company Bioinova,
Ltd. (Prague, Czech Republic) and approved by the State Institute for Drug Control of
the Czech Republic (SUKL, Czech Republic). The mononuclear fraction containing
hMSCs was separated from the bone marrow by gradient centrifugation using 25%
Gelofusine (B. Braun, Melsungen, Germany) and seeded on plastic dishes at a concen-
tration of 5 – 10 × 106 cells/75 cm2. The cells were expanded in media containing
Alpha MEM Eagle without Deoxyribonucleotides, Ribonucleotides and UltraGlutamin
(Lonza, Basel, Switzerland) supplemented with 5% mixed allogeneic thrombocyte lysate
(Bioinova, Prague, Czech Republic) and 10 μg/ml Gentamicin (Lek Pharmaceuticals,
Ljublanja, Slovenia); non-adherent cells were washed out by changing the medium.
When the cells reached 80% confluence, they were detached from the surface of the
dishes using 1 ml/75 cm2 of TrypLE CTS Select™ solution (Gibco, Ca, USA) and re-
seeded at a lower density (5 × 104 per square cm). Cells of the second passage were
analyzed and used in further experiments. The expression of specific surface markers
was assessed using fluorescent-activated cell sorting (FACS) analysis (FACSAria flow
cytometer, BD Biosciences, San Diego, USA). The cells were selected for the following
markers – the presence of CD105, CD73 and CD90 and the absence of CD45, CD34,
CD14 or CD11b, CD79alpha and HLA-DR surface molecules. In order to verify the
differentiation potential of the hMSCs, the cells were differentiated into osteogenic,
chondrogenic and adipogenic lineages using standard differentiation media as described
previously [7]. Cell viability was evaluated according to GMP quality control require-
ments by using trypan blue staining, and the cultures were tested for the presence of
bacterial, fungal and mycoplasma contamination by methods recognized in the European
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clusion method”, article 2.6.1 “Validated cultivational test for sterility” and article
2.6.7 “Mycoplasma detection by validated nucleic acid amplification”. The cells were
frozen in aliquots in saline containing 7.5% dimethylsulfoxide (DMSO, Sigma) and
5% albumin and stored in liquid nitrogen at −160°C until use. The freezing and thawing
process was validated and provided cells with the required phenotype and constant
viability.
For inducing chondrogenesis, cells were harvested, transferred to polypropylene tubes
and differentiated into chondrocytes in pellet cultures (250 000/pellet) in serum-free
medium containing DMEM, dexamethasone (0,1 μM), hTGF-β1 (10 ng/ml), L-ascorbic
acid (0,05 mM), ITS + 1% and Primocin. The tubes were incubated at 37°C in a 5%
CO2 incubator. The medium was changed twice a week. Chondrogenic pellets were
harvested after 20–22 days in culture. The pellets were fixed with 10% formaldehyde,
embedded in parrafin blocks and sectioned into 5 μm sections. Samples were than
stained with Alcian blue.
To induce adipogenic differentiation the cells were seeded in six-well plates at a
density of 10 000 cells/cm2. Cells at confluence were treated with medium containing
DMEM, FBS 10%, dexamethasone (1 μM), 3-isobutyl-1-methyl-xanthine (0,5 mM),
indomethacin (0,1 mM), insulin (10 μg/ml), and Primocin. The medium was changed
twice a week. After 12 days the cells were fixed with 10% formaldehyde and stained
with Oil Red O.
Osteogenesis was induced by seeding the cells in six-well plates at a density of
3000 cells/cm2. Cells were allowed to adhere for 24 hours, and osteogenic medium
containing DMEM, FBS 10% dexamethasone (0,1 μM), β-glycerophosphate (10 mM),
L-ascorbic acid (0,1 mM) and Primocin was added. The medium was changed twice
a week. After 20 days the cells were fixed with 10% formaldehyde and stained with
Alizarin red.Tendon injury
All animal experiments were approved by the Animal Committee of the Czech Republic
and the Animal Care and Use of Animals Committee of the Institute of Experimental
Medicine AS CR. Eighty-one adult rats weighing 400 – 440 g were anesthetized with 2.5%
isoflurane mixed with air. Tendon injury was induced by the application of collagenase to
the middle part of the Achilles tendon, which produces a chemical deterioration of the
tendon tissue accompanied by inflammation in the surrounding tissue. Briefly, the rats’
right legs were fixed in position to achieve 90 degrees bending in the Articulatio talocrur-
alis. After a skin incision, the Achilles tendon was exposed. Tendon injury was induced by
a solution of 0.3 mg collagenase (Sigma) in 25 μl saline injected into the middle part of
the Achilles tendons. The left Achilles tendons were left intact. Rats were randomly di-
vided into two groups. Human MSCs (1 million cells in 100 μl saline) were implanted into
the centre of the tendon lesion of 41 rats, 3 days after injury by a single injection. Forty
rats received 100 μl saline injected in the same regime as the hMSC suspension. Gentami-
cin (Lek Pharmaceutical, 5 mg/kg i.m.) was given continuously for seven days after tendon
injury to prevent post-surgical infection. Immunosuppression was used to prevent the re-
jection of the cell transplants. Cyclosporin (Sandimmun Neoral, Novartis, 10 mg/kg, p.o.)
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one day before cell transplantation. Carprofen (Rimadyl, Pfizer, 1.5 mg/kg, i.m.) was given
twice a day as an analgesic, up to 10 days after tendon injury.Health condition of the animals and gross inspection of the tendons
Animals were examined for motor performance using the Basso-Beattie-Bresnahan
test [8] (routinely used for locomotor evaluation) immediately after awaking from the
anaesthesia, before and after hMSC/saline injection and then randomly during the
whole survival period. The wounds were regularly checked for any pathological events
(inflammation). Each tendon, after isolation and prior to any further biomechanical or
histological evaluation, was visually examined to determine whether there were any
gross differences between the groups in terms of tendon diameter, the presence of tu-
mors, calcifications, hyperemia, synechies and/or the thickness of the petitendoneal
tissues). Evaluations were performed in a blinded fashion by a single investigator.Tissue processing
For histological and immunohistochemical evaluations, the rats were euthanized with
pentobarbital (Sigma, 100 mg/kg, i.p.) 2, 4 or 6 weeks after tendon injury (10 rats with
hMSC treatment and 10 rats with saline at each time-point, Table 1) and transcardially
perfused with phosphate buffered saline (PBS), followed by 4% paraformaldehyde in PBS.
The Achilles tendons were dissected and immersed in 4% paraformaldehyde at 4°C until
further processing.
For biomechanical measurements, the rats were sacrificed with a lethal dose of pento-
barbital (120 mg/kg) 4 weeks after cell transplantation (11 rats with hMSC transplantation
and 10 rats from the control group). The Achilles tendons of both the left and right legs
were removed with the adjacent bone on one side and the muscles on the other side and
left in 4% paraformaldehyde until measurements.Histological processing
Dissected fixed tendons were transferred into 10% and 20% sucrose. After freezing,
the tendons were cryosectioned into longitudinal sections (10 μm thickness), which
were labeled sequentially according to the sectioning order. Around 50 sections were
collected from each tendon, and a similar depth for each staining was selected. For
good reproducibility and comparability, samples from the control and injury groups
were stained at the same time under the same conditions. The sections were examined
using light and fluorescent microscopy. For all sections, the images were taken using
identical light settings. Evaluations were performed in a blinded fashion by a single
investigator.Table 1 Animals
2 weeks 4 weeks 6 weeks Biomechanical study Total
hMSCs 10 10 10 11 41
Saline 10 10 10 10 40
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A histology score based on H&E (hematoxylin and eosin) staining was determined 2, 4
and 6 weeks after tendon injury in both groups. Every 8th coronal section was selected,
and 6 different histologic parameters were semiquantitatively scored from 1 (severe
changes) to 4 (normal) according to the criteria defined in Table 2. Tendon tissues were
evaluated for the linearity of their fibre structure, the shape of the tendon cells, the
density of the tendon cells, inflammation, hemorrhage, and the thickness of the epite-
non, modified from Nixon [9].Immunohistochemistry
Immunoistochemistry was used for the semiquantitative assessment of collagen I and
III, aggrecan and versican, for evaluation of angiogenesis at the site of injury and for
the detection of the presence of hMSCs in the tendon tissue. Detection of collagen II
was used to confirm cartilage formation at the site of injury. Staining was performed
against collagen I (1:500, ABcam), II (1:200, Sigma), III (1:800, ABcam), versican (1:500,
Millipore) and aggrecan (1:1000, Millipore). Neovascularisation was assessed by stain-
ing using RECA-1 (ABcam, 1:50). Immunofluorescent staining for human mitochondria
(anti-Cytochrome c oxidase subunit II antibody, MTCO2, ABcam) was used to identifyTable 2 Histology score
Variable Score and criteria
Linearity of the fiber structure 1 = no linear areas
2 = 20-50% linear
3 = ˃ 50% linear
4 = linear (normal)
Shape of the tendon cells 1 = predominantly round
2 =moderately round
3 = slightly oval
4 = linear (normal)
Density of the tendon cells 1 = sheets of cells
2 = moderate increase
3 = slight increase
4 = sparse(normal)
Inflammation (leucocyte deposits in the endotenon and epitenon) 1 = severe increase
2 = moderate increase
3 = slight increase
4 = none
Hemorrhage 1 = predominant hemorrhage
2 =multiply areas in each field
3 = sparse or patchy
4 = none
Thickness of the epitenon 1 =massive fibrosis
2 = 7–15 cells
3 = 3–6 cells
4 = 1–2 cells
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secondary antibodies conjugated with Alexa-Fluor 488 or 594 (Molecular Probes).Extracellular matrix
Immunohistochemical analysis was used to assess the formation and deposition of col-
lagen type I, collagen type III, aggrecan and versican proteins in every 8th longitudinal
section of the tendons. The extent and intensity of the immunoreactions were graded
on a scale from 1–4, with a score of 1 indicating the absence of antigen expression, a
score of 2 weak and spotted antigen expression, a score of 3 weak, but diffuse antigen
expression throughout the entire repaired site and a score of 4 (diffuse and strong anti-
gen expression).Angiogenesis
RECA immunostaining was used to evaluate angiogenesis within the Achilles tendon
injury. Microscope fields at 40× magnification were centered over the area of Achilles
tendon injury. The vessels within this area were counted in a blinded manner, and the
number of vessels per mm2 was calculated.Osteogenesis
Osteogenesis was detected by Alizarin red and Alcian blue staining. Briefly, sections
prepared as described above were stained with Alizarin red (Sigma) or Alcian blue
(Sigma) for a duration of 20 seconds to 5 minutes; the intensity of the staining was
monitored under a microscope during the staining procedures until red-orange (Alizarin
red) or dark blue (Alcian blue) staining of the structures appeared. The duration of
the staining was different for each set of samples. Alcian blue stained sections were
then counterstained with nuclear red. Subsequently, the glass slides were dehydrated
in absolute alcohol and mounted in mounting medium.Biomechanical testing
An evaluation of the mechanical properties of the rat Achilles tendons was carried out
by destructive tensile tests in order to evaluate their strength and elastic characteristics.
The experiments were performed using the MTS 858 Mini Bionix material testing
system. The tendons were fixed between two metal clamps mounted in pneumatic
clamp grips, ensuring a constant downforce and tough, stable attachment of the sam-
ples during cross-sectional changes. The grips were equipped with diamond-like
apexes. The force impacts were recorded by a sensitive detector with a force range of
500 N (detector error max. 0.05%, e.g. 0.04 N error by the application of 80 N). The
prepared tendons were stored in a physiological solution at 6°C. The mechanical testing
was carried out at room temperature (22°C ±2°C).
The tendons were tested in a bone-to-muscle (BTM) arrangement, i.e. the tendons
were removed with a part of the muscle on one side and with a part of the bone on the
other side. This configuration enabled their secure attachment in the pneumatic clamp
grips during the course of the test, assuming that the muscle tissue was inserted into
liquid nitrogen for 5 sec before applying the load. While implementing this process, we
also checked that the tendons were not frozen. The tendons were removed from the
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anically tested. After fixation, the tendon was pulled at a constant rate of 10.0 mm/min
until failure. We recorded the applied force, the peak force and tendon elongation with
a sampling frequency of 20 Hz.
The evaluation of the assessed data was aimed at discovering the strength and the
elastic characteristics of the tested tendons. The stiffness of the tendons was evaluated
from the course of the loading. The strength of the tendons was evaluated from the
peak force at failure. Another important parameter for evaluating tendon stiffness was
the ratio between the surgically intact (control) tendon and the surgically operated limb
(treated or not treated with hMSCs) of the same animal. In this way, the effect of differ-
ences in the physiques of the animals could be minimized.Statistics
Due to the biological nature of the measured samples, statistically significant differences
were evaluated by nonparametric methods (STATGRAPHICS Centurion XV, StatPoint,
USA). The Kruskal-Wallis test was used for this purpose. The Mann–Whitney test was
used as a post hoc test. A nonparametric analysis of variance was performed at the 95%
confidence level (p = 0.05). Immunohistochemical and histological data are presented as
mean ± standard deviation. The mean values for comparing the biomechanical data were
calculated mainly as medians. The intervals for each median were calculated as the inter-
quartile range (IQR). For comparative purposes, the mean values were also calculated as
an arithmetical average, and their confidence intervals (CI) were calculated on the basis of
t-statistics at the 95% confidence level (p = 0.05).Results
Cell isolation and cultivation
The GMP production of hMSCs was validated before the experiments. More than 90%
of the cells simultaneously expressed CD105, CD73 and MHC I Class while being
negative for CD45 and CD34; the preparations were sterile and without the presence
of endotoxins or mycoplasma. The content of contaminating cells (i.e., cells displaying
the positive expression of CD34, CD16, CD19, CD3, CD14 or CD79alpha) was below
5% in all samples. Cell viability was more than 95% before transplantation. Staining for
MTCO2 (human mitochondria - Cytochrome c oxidase subunit II) confirmed the
presence of transplanted hMSCs in the site of injury 2, 4 and 6 weeks after transplant-
ation (Figure 1I).Health condition of the animals and gross inspection of the tendons
After animals awoke from the anaesthesia, no differences were observed between the
saline and hMSC groups in the BBB motor performance test. The animals had a ten-
dency to not use the lesioned limb and the stability of their trunk was altered; but after
three days the animals fully recovered, and the injection of hMSCs/saline did not influ-
ence their motor performance. The wounds of 3 rats belonging to the saline-treated
group needed to be resutured due to the animals’ activity. There were no gross failures
detected by tendon anatomo-pathological observation in either group.
Figure 1 Histology. Hematoxylin-eosin sections show the improvement of tendon ultrastructure in control
(A-C) and hMSC-treated (D-F) groups 2, 4 and 6 weeks after tendon injury. Better organization of the
extracellular matrix was observed after hMSC treatment compared to the saline-treated tendons (Scores
A-7, B-12, C-13, D-11, E-14, F 17). The formation of cartilage and bone was confirmed by collagen II staining,
6 weeks after injury (G,H). Mesenchymal stromal cells survived at the site of the lesion as confirmed by
MTCO2 staining (I).
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Semiquantitative immunohistological analysis showed an increase of collagen III
immunopositivity, and the scores of the hMSC-treated group were significantly higher
4 and 6 weeks after tendon injury (Figure 2A). Similarly, collagen I immunopositivity
reached significantly higher scores 4 and 6 weeks after injury in the hMSC-treated
group (Figure 2B). The aggrecan semiquantitative immunopositivity score remained
stable during the 6 week survival period in both groups, and no statistically significant
difference was found between the groups (Figure 2C). The versican semiquantitative
score rose during the entire survival period in both groups, but differences between
the groups did not reach statistical significance (Figure 2D).Histology score
Six weeks after tendon injury, the wounds were observed to be filled with connective
tissue in both groups. The hMSC-treated group achieved a significantly better histology
score (Figure 2E) thanks to their lower cellularity with the presence of more spindle-
shaped cells, a denser tissue matrix, better vascularity and better organization of the
collagen fibers (Figure 1D-F). P values less than 0.05 were considered significant.Angiogenesis
We observed excessive angiogenesis 14 days and 28 days after Achilles tendon injury in
both groups. Forty-two days after injury, angiogenesis decreased in both the hMSC-treated
Figure 2 Graphs. (A-D) Graphes showing the time course of the semiquantitativly evaluated intensity of the
extracellular matrix. (A, B) Intensity of collagen I and collagen III staining reached statistical significance 4 and
6 weeks after tendon injury (p < 0.05) (C, D) Aggrecan and versican semiquantitative grading showed no statistical
differences between the hMSC-treated and control groups (E) Hematoxylin end eosin stained sections were evalu-
ated for different criteria (linearity of their fibre structure, the shape of the tendon cells, the density of the tendon
cells, inflammation, hemorrhage, and the thickness of the epitenon) and cumulative score are presented in the
graph showing that hMSC-treated tendons had significantly higher scores 6 weeks after tendon injury (F). The
number of blood vessels per mm2 in the center of the lesion was calculated 2 and 6 weeks after tendon injury;
neovascularization significantly increased in the hMSC-treated tendons.
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was significantly higher in the hMSC-treated group 14 and 28 days post-injury, while no
difference between the groups was observed 42 days after Achilles tendon injury (P < 0.05).Osteogenesis
We analysed osteogenesis within the damaged or treated tendons using Alizarin red
stained sections. In 2 controls (20%) and 6 hMSC-treated animals (55%), there were
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were surrounded by a thin layer of hyalinous cartilage (Figure 1H).Biomechanical testing
The mechanically evaluated samples were divided into four groups. Group A contained
intact tendons, while Group B contained tendons with a collagenase-induced lesion
that was not treated by hMSC transplantation (operated). Group C contained intact
tendons, and Group D contained lesioned tendons treated with an application of
hMSCs. Groups A and B were taken from the same animal (left and right leg), similarly
Groups C and D. The final mean peak force values assessed at tendon failure are listed
in Table 3. The mean peak force values at failure of the operated tendons not treated
with an application of hMSCs (Group B) were about the same as the values for the
intact tendons (Group A); Mann–Whitney post hoc test (p = 0.05), for an illustration
see Figure 3A. Similarly, the mean peak force values at failure of surgically operated
tendons treated with an application of hMSCs (Group D) were about the same as the
values for the intact tendons (Group C); Mann–Whitney post hoc test (p = 0.05). The
ratios of the peak force at failure (B/A and D/C) were calculated for further verification
of the influence of hMSC treatment (see Figure 3B). In Figure 3B, Group I represents
the peak force ratios of hMSC-untreated defects, and Group II represents the peak
force ratios of hMSC-treated defects. In this case as well, no statistically significant dif-
ferences were found at the 95% confidence level.
The evaluation of elastic characteristics represents an assessment of Achilles tendon
stiffness, which was calculated from a linear portion of the elastic phase of the
load–displacement curve from the tensile test (see Figure 3E). The final mean
tendon stiffness values are listed in Table 4. There were no statistically significant
differences (p = 0.05) between the lesioned tendons not treated with an application
of hMSCs (Group B) and the intact tendons (Group A), evaluated using the Mann–
Whitney post hoc test. Similarly, there were no differences between the stiffness of
the surgically operated tendons treated with an application of hMSCs (Group D)
and the stiffness of the intact tendons (Group C), again using the Mann–Whitney
post hoc test (p = 0.05); for an illustration see Figure 3C. The stiffness ratios (B/A
and D/C) were calculated for further verification of the influence of hMSC treat-
ment (see Figure 3D). In Figure 3D, Group I represents the stiffness ratios of
hMSC-untreated defects, and Group II represents the stiffness ratios of hMSC-
treated defects. In this case, too, no statistically significant differences could be
found at the 95% confidence level. However, it should be pointed out that we found
the highest confidence level for the presence of statistically significant differencesTable 3 Biomechanical testing mean peak force values
Fmax [N]
Group A Group B Group C Group D
Median 79.2 73.4 64.4 62.1
IQR [64.8; 91.2] [58.1; 84.4] [63.0; 71.2] [59.1; 76.2]
Average 77.8 73.2 64.8 65.2
CI (p = 0.05) [66.8; 88.7] [63.7; 82.7] [54.2; 75.2] [56.7; 73.6]
Figure 3 Biomechanical testing. (A) Box-and-Whiskers plot of the peak forces measured at tendon failure.
(B) Ratio of the peak forces assessed at failure in intact and surgically treated tendons. (C) Box-and-Whiskers
plot of the tendon stiffness. (D) Ratio of the stiffness of intact and surgically treated tendons. (E) A representative
characteristic load–displacement curve from a tensile test of an Achilles tendon. Groups A and C contain intact
(unoperated) tendons, group B contains surgically operated tendons without the application of mesenchymal
stromal cells (hMSCs), group D contains surgically operated tendons with the application of hMSCs. Group I
represents animals without hMSC treatment. Group II represents animals with hMSC treatment. The grey boxes
indicate the interquartile range, the whiskers indicate the 10–90 percentile range, and the small red circles
indicate values more than 1.5 times IQR above or below the boxes (○). Any points more than 3 times IQR above
or below the box are indicated by circles with superimposed plus signs (⨁). A horizontal line is drawn at the
median. The plus signs inside the boxes indicate the arithmetical averages.
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significant differences were found at the 90.3% confidence level. Statistically signifi-
cant differences in the comparison between Group A and Group B were found at
the 52% confidence level. We can therefore conclude that in this experimental
design, the application of hMSCs could result in interesting effects – an increase in
the stiffness of the tested tendons.Table 4 Biomechanical testing stiffness values
Stiffness [N.mm−1]
Group A Group B Group C Group D
Median 24.5 19.8 16.6 19.6
IQR [16.3; 31.9] [15.4; 27.0] [14.1; 20.9] [18.0; 25.6]
Average 25.5 21.3 17.9 21.9
CI (p = 0.05) [18.7; 31.7] [17.3; 25.3] [12.9; 22.9] [18.0; 25.8]
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Our main objective was to test the safety and effectiveness of human mesenchymal
stromal cells transplanted 3 days after a collagenase tendon injury. No differentiation
protocols were applied to the hMSCs, therefore their effect was dependent only on fac-
tors such as mechanical factors [10], paracrine signalling [11,12] and/or interleukins
[13-15] present within the injured tendon. The inflammatory environment and the
hypoxic conditions in the tendon also play an important role in cell behaviour, which
cannot be completely replicated by in vitro experiments. This process can be com-
pared to the differentiation protocol described by Lovati et al.; briefly, equine bone
marrow MSCs were co-cultured with tendon tissue fragments in a transwell system
[1]. In these experiments, 5% human platelet lysate was utilized as a culture supple-
ment, as described by Warnke et al., who used 10% human platelet lysate for MSC
propagation [16]. A similar effect on osteodifferentiation was previously described by
Chevallier, Parsons and Prinse [17-19]; this effect can be related to the age of the plate-
let donors [20]. Other authors have cast doubts on the influence of platelet lysate on
osteogenic differentiation [21-23]. Further experiments in this area are needed in
order to utilize expanded hMSCs in therapeutic protocols for tendon healing because
osteogenesis in tendons is undesirable and must be prevented.
The present results provide evidence that hMSCs enhance the healing processes in the
rat after chemically induced tendon injuries. The production of collagen I, collagen III and
versican increased during the 6 week survival period, and in the hMSC-treated group both
types of collagen deposits reached a statistically significantly elevated level over the level
seen in the saline-treated group. This production could be related to the direct synthesis
of extracellular matrix proteins by the hMSCs during their maturation [24].
The structure and organization of the tendon tissue – expressed as a histology score –
showed better organization of the extracellular matrix and lower cellularity in the
hMSC-treated group. The level of aggrecan expression remained stable and was similar
in the control and hMSC-treated tendons; other authors found that increased aggrecan
mRNA expression is associated with painful tendinopathy [25]. As repeatedly described
previously, hMSC transplantation had a strong influence on neovascularization [26]. In
our experiments, 2 and 4 weeks after tendon injury the number of vessels in the
hMSC-treated group was significantly higher at the site of injury. Versican expression
has been detected in many tissues, including the brain, smooth muscles, cartilage and
tendons [27]. Our semiquantitative immunohistochemical evaluation showed that the
expression of versican non-significantly increased in the hMSC-treated group. Corps
et al. [25] reported that a decreased level of versican was present in the tissue of painful
and ruptured tendons. They concluded that decreased versican mRNA expression can
contribute to alter matrix structure and function in chronic tendinopathy and ruptured
tendons. Our semiquantitative immunoistochemical evaluation showed that the expres-
sion of versican protein was not influenced by hMSC implantation.
Collagen II positivity, Alcian blue and Alizarin red staining were used to investigate
the formation of cartilage and bone at the site of injury. In three rats from the saline-
treated group (30%) and eight rats from the hMSC-treated group (73%), the presence
of newly formed cartilage at the site of injury was detected. It is probable that the
cartilage was developing towards the bone that was present in 20% of controls and 55%
of hMSC-treated tendons. The low vascularity of the tendon and the very dense
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the cells. hMSCs cultured under hypoxic conditions expressed higher levels of osteo-
blastic and adipocytic differentiation markers than normoxic controls [28]. Different
protocols for increasing tenogenic differentiation and decreasing the risk of ectopic
cartilage and bone formation using, e.g., growth and differentiation factors 5 and 6,
have been developed [29,30]; however, before translation of the protocols to the clinical
environment, their safety should be well documented.
Biomechanical testing of stiffness and load to failure did not result in differences be-
tween the groups. However, the stiffness of the tendons improved after the application
of hMSC treatment at the 90% confidence level (27-85% taking into account the lower
and upper quartiles, 18% taking into account the medians). From the point of view of
the mechanical testing of biological materials, we can consider the 90% confidence level
as a sufficient result; however, more in vivo experimental work is needed to clarify this.
While lower than the widely used 95% and 99% confidence levels, the 90% confidence
level in statistical hypothesis testing theory can indicate useful experimental effects. Ac-
cording to previous publications [31,32], we decided to test the biomechanical proper-
ties of the tendons 4 weeks after injury. However, as was shown in our results, the
reorganization of the extracellular matrix and the healing processes still continued for
another two weeks. Also, the vascularity of the tendon tissue was very high 4 weeks
after injury and then decreased. Neovascularization is an important part of the healing
process and ultimately enhances tendon regeneration, but it actually could change the
mechanical properties of the tendon and affect the results between groups.Conclusions
Human multipotent mesenchymal stromal cells, when implanted into artificially induced
tendinitis, promote neovascularization and tissue organization. The implantation may
increase the stiffness of the tendons; however, more experiments are needed to clarify
this point. The treatment procedure is safe, no tumor formation or excessive inflam-
matory reaction were detected; nonetheless, cartilage formation at the implantation
site occurred in a few cases, and this should be taken into account when planning
subsequent in vivo and clinical trials as an expected adverse event.
Abbreviations
hMSCs: Human mesenchymal stromal cells; IQR: Interquartile range; CI: Confidence intervals; RECA: Anti-endothelial cell
antibody; MTCO2: Anti-cytochrome c oxidase subunit II antibody; GMP: Good manufacturing practice; BBB: Basso-
Beattie-Bresnahan motor performance test; H&E: Hematoxylin and eosin staining.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
LMU and TA designed the experiments, performed the surgery of the rats, collected samples, evaluated the samples,
performed histology and immunohistochemistry, analyzed the data and drafted the manuscript. RS and TS were
involved in the biomechanical testing of the tendons, interpretation of the data and drafting of the manuscript. PL
and PJ were involved in expanding and quality control of the mesenchymal stem cells, VH were involved in animal
care and designing of experiments, ES interpreted data, designed study and critically revised the manuscript. JR was
involved in statistical evaluation of immunohistochemistry, mesenchymal stem cells cultivation and prepared second
and third revision of the manuscript. All authors approved the final manuscript.
Acknowledgements
Supported by the grant project GAČR - P304/10/0326, grant CZ.1.05/1.1.00/02.0109 and the research institution grant
project No. 00064203.
Machova Urdzikova et al. BioMedical Engineering OnLine 2014, 13:42 Page 14 of 15
http://www.biomedical-engineering-online.com/content/13/1/42Author details
1Institute of Experimental Medicine, Academy of Sciences of the Czech Republic, Prague, Czech Republic. 2Department
of Neuroscience, Charles University, Second Faculty of Medicine, Prague, Czech Republic. 3Department of Orthopedics
and Traumatology, Charles University, 2nd Faculty of Medicine, Prague, Czech Republic. 4Laboratory of Biomechanics,
Department of Mechanics, Biomechanics and Mechatronics, Faculty of Mechanical Engineering, Czech Technical
University in Prague, Prague, Czech Republic.
Received: 1 November 2013 Accepted: 1 April 2014
Published: 9 April 2014
References
1. Lovati AB, Corradetti B, Cremonesi F, Bizzaro D, Consiglio AL: Tenogenic differentiation of equine mesenchymal
progenitor cells under indirect co-culture. Int J Artif Organs 2012, 35(11):996–1005.
2. Pacini S, Spinabella S, Trombi L, Fazzi R, Galimberti S, Dini F, Carlucci F, Petrini M: Suspension of bone
marrow-derived undifferentiated mesenchymal stromal cells for repair of superficial digital flexor tendon in
race horses. Tissue Eng 2007, 13(12):2949–2955.
3. Havlas V, Kotaška J, Lesný P, Sevastyanova O, Trč T: Effect of PRP on healing of arthroscopic rotator cuff repair
first experience. Ortopedie 2013, 7:6–9.
4. Ahmad Z, Wardale J, Brooks R, Henson F, Noorani A, Rushton N: Exploring the application of stem cells in
tendon repair and regeneration. Arthroscopy 2012, 28(7):1018–1029.
5. Kida Y, Morihara T, Matsuda K, Kajikawa Y, Tachiiri H, Iwata Y, Sawamura K, Yoshida A, Oshima Y, Ikeda T, Fujiwara
H, Kawata M, Kubo T: Bone marrow-derived cells from the footprint infiltrate into the repaired rotator cuff.
Journal of shoulder and elbow surgery/American Shoulder and Elbow Surgeons 2013, 22(2):197–205.
6. Ruzzini L, Longo UG, Rizzello G, Denaro V: Stem cells and tendinopathy: state of the art from the basic science
to clinic application. Muscles Ligaments Tendons J 2012, 2(3):235–238.
7. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz
E: Minimal criteria for defining multipotent mesenchymal stromal cells. International Society Cellular Therapy
Cytotherapy 2006, 8(4):315–317.
8. Basso DM, Beattie MS, Bresnahan JC: A sensitive and reliable locomotor rating scale for open field testing in
rats. J Neurotrauma 1995, 12(1):1–21.
9. Nixon AJ, Dahlgren LA, Haupt JL, Yeager AE, Ward DL: Effect of adipose-derived nucleated cell fractions on
tendon repair in horses with collagenase-induced tendinitis. Am J Vet Res 2008, 69(7):928–937.
10. Kuo CK, Tuan RS: Mechanoactive tenogenic differentiation of human mesenchymal stem cells. Tissue Eng Part
A 2008, 14(10):1615–1627.
11. Ohnishi S, Sumiyoshi H, Kitamura S, Nagaya N: Mesenchymal stem cells attenuate cardiac fibroblast
proliferation and collagen synthesis through paracrine actions. FEBS Lett 2007, 581(21):3961–3966.
12. Sharma RI, Snedeker JG: Paracrine interactions between mesenchymal stem cells affect substrate driven
differentiation toward tendon and bone phenotypes. PLoS One 2012, 7(2):e31504.
13. Huang GT, Gronthos S, Shi S: Mesenchymal stem cells derived from dental tissues vs those from other
sources: their biology and role in regenerative medicine. J Dent Res 2009, 88(9):792–806.
14. Chowdhury A, Bezuidenhout LW, Mulet-Sierra A, Jomha NM, Adesida AB: Effect of interleukin-1beta treatment
on co-cultures of human meniscus cells and bone marrow mesenchymal stromal cells. BMC Musculoskelet
Disord 2013, 14:216.
15. Rattigan Y, Hsu JM, Mishra PJ, Glod J, Banerjee D: Interleukin 6 mediated recruitment of mesenchymal stem
cells to the hypoxic tumor milieu. Exp Cell Res 2010, 316(20):3417–3424.
16. Warnke PH, Humpe A, Strunk D, Stephens S, Warnke F, Wiltfang J, Schallmoser K, Alamein M, Bourke R, Heiner P,
Liu Q: A clinically-feasible protocol for using human platelet lysate and mesenchymal stem cells in
regenerative therapies. J Craniomaxillofac Surg 2013, 41(2):153–161.
17. Chevallier N, Anagnostou F, Zilber S, Bodivit G, Maurin S, Barrault A, Bierling P, Hernigou P, Layrolle P, Rouard H:
Osteoblastic differentiation of human mesenchymal stem cells with platelet lysate. Biomaterials 2010, 31(2):270–278.
18. Parsons P, Butcher A, Hesselden K, Ellis K, Maughan J, Milner R, Scott M, Alley C, Watson JT, Horner A: Platelet-rich
concentrate supports human mesenchymal stem cell proliferation, bone morphogenetic protein-2
messenger RNA expression, alkaline phosphatase activity, and bone formation in vitro: a mode of action to
enhance bone repair. J Orthop Trauma 2008, 22(9):595–604.
19. Prins HJ, Rozemuller H, Vonk-Griffioen S, Verweij VG, Dhert WJ, Slaper-Cortenbach IC, Martens AC: Bone-forming
capacity of mesenchymal stromal cells when cultured in the presence of human platelet lysate as substitute
for fetal bovine serum. Tissue Eng Part A 2009, 15(12):3741–3751.
20. Lohmann M, Walenda G, Hemeda H, Joussen S, Drescher W, Jockenhoevel S, Hutschenreuter G, Zenke M, Wagner
W: Donor age of human platelet lysate affects proliferation and differentiation of mesenchymal stem cells.
PLoS One 2012, 7(5):e37839.
21. Gruber R, Karreth F, Kandler B, Fuerst G, Rot A, Fischer MB, Watzek G: Platelet-released supernatants increase
migration and proliferation, and decrease osteogenic differentiation of bone marrow-derived mesenchymal
progenitor cells under in vitro conditions. Platelets 2004, 15(1):29–35.
22. Horn P, Bokermann G, Cholewa D, Bork S, Walenda T, Koch C, Drescher W, Hutschenreuther G, Zenke M, Ho AD,
Wagner W: Impact of individual platelet lysates on isolation and growth of human mesenchymal stromal
cells. Cytotherapy 2010, 12(7):888–898.
23. Kumar A, Salimath BP, Stark GB, Finkenzeller G: Platelet-derived growth factor receptor signaling is not involved
in osteogenic differentiation of human mesenchymal stem cells. Tissue Eng Part A 2010, 16(3):983–993.
24. Bernstein P, Sticht C, Jacobi A, Liebers C, Manthey S, Stiehler M: Expression pattern differences between
osteoarthritic chondrocytes and mesenchymal stem cells during chondrogenic differentiation.
Osteoarthritis Cartilage 2010, 18(12):1596–1607.
Machova Urdzikova et al. BioMedical Engineering OnLine 2014, 13:42 Page 15 of 15
http://www.biomedical-engineering-online.com/content/13/1/4225. Corps AN, Robinson AH, Movin T, Costa ML, Hazleman BL, Riley GP: Increased expression of aggrecan and
biglycan mRNA in Achilles tendinopathy. Rheumatology (Oxford) 2006, 45(3):291–294.
26. Tang YL, Zhao Q, Zhang YC, Cheng L, Liu M, Shi J, Yang YZ, Pan C, Ge J, Phillips MI: Autologous mesenchymal
stem cell transplantation induce VEGF and neovascularization in ischemic myocardium. Regul Pept 2004,
117(1):3–10.
27. Yamagata M, Shinomura T, Kimata K: Tissue variation of two large chondroitin sulfate proteoglycans (PG-M/
versican and PG-H/aggrecan) in chick embryos. Anat Embryol 1993, 187(5):433–444.
28. Grayson WL, Zhao F, Izadpanah R, Bunnell B, Ma T: Effects of hypoxia on human mesenchymal stem cell
expansion and plasticity in 3D constructs. J Cell Physiol 2006, 207(2):331–339.
29. Chai W, Ni M, Rui YF, Zhang KY, Zhang Q, Xu LL, Chan KM, Li G, Wang Y: Effect of growth and differentiation
factor 6 on the tenogenic differentiation of bone marrow-derived mesenchymal stem cells. Chin Med J (Engl)
2013, 126(8):1509–1516.
30. Tan Q, Lui PP, Rui YF: Effect of in vitro passaging on the stem cell-related properties of tendon-derived stem
cells-implications in tissue engineering. Stem Cells Dev 2012, 21(5):790–800.
31. Awad HA, Butler DL, Boivin GP, Smith FN, Malaviya P, Huibregtse B, Caplan AI: Autologous mesenchymal stem
cell-mediated repair of tendon. Tissue Eng 1999, 5(3):267–277.
32. Gulotta LV, Kovacevic D, Packer JD, Deng XH, Rodeo SA: Bone marrow-derived mesenchymal stem cells
transduced with scleraxis improve rotator cuff healing in a rat model. Am J Sports Med 2011, 39(6):1282–1289.doi:10.1186/1475-925X-13-42
Cite this article as: Machova Urdzikova et al.: Human multipotent mesenchymal stem cells improve healing after
collagenase tendon injury in the rat. BioMedical Engineering OnLine 2014 13:42.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
